Two Lilly-adjacent paths, one CMS stamp
LillyDirect is the manufacturer's cash and home-delivery channel. As of 19 August 2026, Foundayo's lowest-dose cash often starts near $149. Zepbound cash is a separate list and a separate device choice.
Medicare GLP-1 Bridge is a CMS demonstration: $50 per month, 1 July 2026–31 December 2027, for Foundayo and for Zepbound KwikPen (plus Wegovy, which is not a Lilly product). A clinician files the PA. LillyDirect does not file it.
Who may use which
Bridge: Part D or MA-PD, generally no 2026 Part D GLP-1 fill, matching BMI tier, demonstration indication, listed product. Extra Help does not reduce the $50. The $50 does not count toward TrOOP.
LillyDirect cash: anyone the manufacturer will sell to at cash terms. It does not require Bridge eligibility. It does not create Part D credit. Government beneficiaries still cannot bolt a commercial savings card onto the sale.
Device trap on only one path
On Bridge, Zepbound must be KwikPen. On LillyDirect, other presentations may appear. Buying a non-KwikPen cash pen does not later convert into a $50 demonstration fill.
When cash is still rational
PA denied, ineligible, wrong indication for Bridge, or the person wants Foundayo now while the clinician checklist is still being scheduled. $149–the then-current Zepbound cash still usually beats a telehealth bundle near $449.
What not to tell the pharmacy
Do not ask LillyDirect to 'bill Bridge.' Do not ask the Bridge processor to match a cash invoice. Pick a path and keep the receipts in the correct folder.
Questions
If I start on LillyDirect, can I switch to Bridge later?
Does LillyDirect apply Extra Help?
Is Wegovy on LillyDirect?
Which path does VitalHound prefer?
Not sure this applies to you?
Answer a few questions and see your own numbers.
Free to see which path is likely cheapest for your coverage.
Check my options